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Simvastatin is among the most commonly used prescription medications for
cholesterol reduction and the most common statin-related adverse drug reaction
is skeletal muscle toxicity. Multiple factors have been shown to influence
simvastatin-induced myopathy. In addition to age, gender, ethnicity, genetic
predisposition, and dose, drug-drug interactions play a major role. This is
particularly true for drugs that are extensively metabolized by cytochrome P450
(CYP)3A4. We describe a particularly severe case of rhabdomyolysis after the
introduction of ciprofloxacin, a weak CYP3A4 inhibitor, in a patient who previously
tolerated the simvastatin-amlodipine combination
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Simvastatin is among the most commonly used prescription medications for cholesterol reduction and the most common statin-
related adverse drug reaction is skeletal muscle toxicity. Multiple factors have been shown to influence simvastatin-induced
myopathy. In addition to age, gender, ethnicity, genetic predisposition, and dose, drug-drug interactions play a major role. This
is particularly true for drugs that are extensively metabolized by cytochrome P450 (CYP)3A4. We describe a particularly severe
case of rhabdomyolysis after the introduction of ciprofloxacin, a weak CYP3A4 inhibitor, in a patient who previously tolerated the
simvastatin-amlodipine combination.
1. Introduction
Extremely severe rhabdomyolysis with statin therapy remains
rare, in comparison with myalgias or mild elevation of
muscular enzymes. Among precipitating factors, drug-drug
interactions are playing an important role and should be
investigated in depth. We are reporting a case of impressive
rhabdomyolysis occurring soon after the introduction of
antimicrobial therapy in patient who acquired peritoneal
dialysis-related peritonitis.
2. Case Report
A 41-year-old African woman presented to the hospital
for diffuse myalgia and intense weakness developing over
the last 3 days. Her previous medical history included
systemic lupus erythematosus (SLE) complicated by severe
glomerulonephritis. After progression of renal failure, she
required peritoneal dialysis (PD) for the last 3 years. She
was on automated PD with 3 exchanges of 1,800mL dur-
ing the night and fill volume of 1,500mL with icodextrin
during daytime. Current medications included furosemide
125mg b.i.d., amlodipine 10mg o.d., bisoprolol 10mg o.d.,
irbesartan 300mg o.d., mycophenolate mofetil 500mg o.d.,
hydroxychloroquine 200mg b.i.d., calcium carbonate 1 g
b.i.d., colecalciferol 625𝜇g weekly, sevelamer 800mg b.i.d.,
calcitriol 0.25 𝜇g three times a week, and simvastatin 20mg
o.d. Adherence to treatment was good and nomodification in
type or doses of any of these medications was done since the
last 12months.The patient had a residual creatinine clearance
of 5mL/min. Nine days before admission, she was diagnosed
with a peritoneal dialysis-related peritonitis (PDRP) based
on the cloudy aspect of the peritoneal dialysis effluent
(PDE) with 1,300 cells/𝜇L and 47% neutrophils. She was at
this time poorly symptomatic with no fever or abdominal
discomfort and was given empiric antimicrobial therapy with
vancomycin 2,000mg/3d, ciprofloxacin 500mg b.i.d., and a
single dose of gentamicin 80mg according to our protocol [1].
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Four days later, culture of the PDE grew for Corynebacterium
striatum and ciprofloxacin was withdrawn. The next day, she
started to complain of diffuse severemuscle pain with intense
weakness and the PDE color appeared reddish. The patient
became also progressively anuric. On admission, laboratory
investigations showed an impressive rhabdomyolysis with
creatine kinase (CK) 540,000 IU/L (𝑁 < 200), lactate
dehydrogenase (LDH) 19,200 IU/L (𝑁 < 248), and aspartate
aminotransferase 1,700 IU/L (𝑁 < 50). Urine output before
the incidence of rhabdomyolysis was 1,500mL/day. Serum
creatinine value peaked at 12.4mg/dL (usual value was
9mg/dL). Severe electrolyte disorders were observed with
potassium 6.3mmol/L, phosphorus 12.8mg/dL, and ionized
calcium 2.9mg/dL.The patient denied any recent ingestion of
a substance or drug other than the prescribed antimicrobial
therapy and she reported no recent strenuous exercise. Urine
toxicological analysis was negative for opioids and cocaine.
No biological sign was consistent with a progression of
SLE (anti-DNA antibodies 3.2U/mL (𝑁 < 8), C3 and
C4 complement components, respectively, 82mg/dL (𝑁: 85–
193) and 38mg/dL (𝑁: 10–40)). Thyroid function tests were
normal. Blood cultures remained sterile and Epstein-Barr
virus, cytomegalovirus, human immunodeficiency virus, and
influenza A and B serologies were negative.
She was admitted to the intensive care unit (ICU) for the
correction of electrolyte disorders and fluid balance. Serum
CK peaked at 816,000 IU/L on day 2 and then progressively
decreased. Peritoneal dialysis therapy was maintained (3
exchanges/day) and PDE progressively cleared. Peritonitis
also progressively resolved. Renal function recovered par-
tially with spontaneous reapparition of dark tea-colored
urine output (600mL/d). A right vastus lateralis needle
muscle biopsy was performed. The biopsy was of small size
and was normal except for increased size and amount of
lipid droplets. Serum carnitine and acylcarnitine levels were
normal. Lymphocyte carnitine palmitoyl-CoA transferase 2
activity was increased.
Genetic analysis was performed to identify potential
gene variants responsible for altered absorption, distribu-
tion, metabolism, and excretion of statins and/or for higher
susceptibility to myopathy. The patient was cytochrome
P-450 (CYP) 3A4∗1/∗1 (absence of reduced activity ∗22
allele), CYP3A5∗1/∗1 (absence of inactive ∗3 allele rend-
ing the patient CYP3A5 expressor), influx transporter gene
SLCO1B1∗1b/∗1b (absence of reduced activity ∗5 allele con-
sidered as the main genetic risk factor for developing
myopathy after simvastatin intake), and efflux transporter
gene ABCB1 heterozygote 3435CT. Electrolyte disorders were
corrected and the patient left the ICU on day 3. At 3-
month follow-up, serum creatinine returned to previous
values, while the patient was still on PD and had a complete
functional recovery.
3. Discussion
This patient developed a severe rhabdomyolysis soon after
the introduction of an antimicrobial therapy for a PDRP.
The pathogen that was identified, namely, Corynebacterium
striatum, is not the most common one but was still found
in 5% of culture positive PDRP [2]. It is usually transmitted
from the skin following errors ofmanipulation by the patient.
The paucity of symptoms and the poor neutrophilic response
are frequent and consistent with the indolent pattern of this
microorganism.
Among the main etiologies of rhabdomyolysis (trauma-
tism, exertion, muscle hypoxia, genetic defects, infection,
hypo- or hyperthermia, and metabolic and electrolyte dis-
orders), drugs and toxins are playing a significant role [3,
4]. Among the latter, statins, fibrates, alcohol, heroin, and
cocaine are the commonest agents.
Statins are widely prescribed in developed countries.
Although generally safe, they can induce muscle disorders
ranging from myalgias without any biologic abnormality to
life-threatening rhabdomyolysis. Statin-related rhabdomyol-
ysis (SRR), usually defined as CK levels exceeding 10 times
the upper limit of normal range, is reported to be very
infrequent (in comparison with myopathy or myalgias), with
an incidence of 0.01% for five-year therapy [5], that is, 0.04–
0.12 cases per million prescriptions [6]. A recent review of
literature data (1990–2013) identified 112 cases classified as
rhabdomyolysis, and simvastatinwas frequently cited (55/112)
[7]. In about half of the cases of SRR, rhabdomyolysis could
be precipitated by an interaction between statin and a new
prescribed drug that is believed to interfere with statin
metabolism [6, 7].
Statins metabolism varies from one type to another.
After passive absorption by the intestinal cells, simvastatin
is transported from the portal blood to the hepatocytes by
an influx pump, the organic anion-transporting polypeptide
1B1 (OATP1B1). Simvastatin is an inactive lactone that is
then predominantly (≥80%) metabolized by CYP3A4 and
3A5 with a little contribution of CYP2A8 (≤20%) into 𝛽,𝛿-
dihydroxy acid, its active metabolite [8]. The metabolism
is almost complete after hepatic first pass. Drugs inhibiting
CYP3A4 such as azole antifungals, HIV protease inhibitors,
macrolides, cyclosporine, verapamil, diltiazem, amiodarone,
and grapefruit juice may increase serum simvastatin level
and its toxicity. Sensitivity to those interactions varies from
one patient to another due to heterogeneous CYP3A4
activity among individuals [6]. Ciprofloxacin is a known
weak inhibitor of CYP3A4 and may thus inhibit simvastatin
metabolism, increasing its myotoxicity. Amlodipine has also
been shown to competitively inhibit the metabolic activity
of CYP3A4/5. A pharmacokinetic interactionmodel revealed
that coadministration of simvastatin with 10mg amlodipine
could significantly increase simvastatin bioavailability and
decrease simvastatin clearance, but also that these changes
could be minimized by using a simvastatin dose lower than
24mg [9, 10].
While an interaction between statins and other drugs on
the CYP3A4 metabolic pathway is well known, the implica-
tion of other mechanisms has been suggested. Among these,
glycoprotein P (P-gp) inhibition could play a role. P-gp is an
active tissue-specific drug transporter belonging to the ATP-
binding cassette superfamily. Acting as an efflux pump, it
avoids cellular uptake of several drugs and toxins, preventing
notably their absorption through the gastrointestinal tract.
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As simvastatin is not only an inhibitor but also a substrate
of the P-gp, inhibition of P-gp by other drugs may increase
serum levels of simvastatin when coadministered [11]. If P-gp
interaction between ciprofloxacin and simvastatin has been
suggested in a similar case report, there is currently still
controversy to whether ciprofloxacin could be a substrate
of P-gp [12]. Additionally, amlodipine is devoid of P-gp
inhibiting properties [10].
The multiple drug protein 2 (MRP2) is another mem-
brane transport protein from the ABC superfamily excreting
toxins into bile that could play a role in drug-drug interac-
tions as simvastatin is also a substrate of this transporter [13].
Several genetic factors may predispose to statin-related
toxicity [14]. If gene variants coding for CYP3A4/5, the mito-
chondrial enzyme GATM, the influx transporter OATP1B1
(encoded by SLCO1B1), and the efflux transporters P-gp
(encoded by ABCB1) have a theoretical potential for affect-
ing absorption, distribution, metabolism, and excretion of
statins, only the∗5 allele of SLCO1B1 has been strongly identi-
fied to be clinically associated with statin induced myopathy,
especially for simvastatin [14, 15]. The SLCO1B1∗5 allele
disrupts the localization of the OATPB1 influx transporter
reducing the hepatic uptake of statins and increasing their
plasma level and so their toxicity. Our patient was not found
to be carrier of this allele. Her 3435CT heterozygote status for
ABCB1 could not be theoretically associated with a decreased
P-gp activity.
To date, only two other cases of rhabdomyolysis after drug
interaction between simvastatin and ciprofloxacin have been
reported, but nonewith a simvastatin-amlodipine interaction
[16, 17].
Several other risk factors for SRR could also have influ-
enced the severity of the rhabdomyolysis in our patient.
First, CK levels are known to be higher in black people [18].
Secondly, SLE may be associated with a certain degree of
latent myositis, even if no sign of progression of SLE was
found in our patient. Third, the patient had terminal renal
failure requiring PD. However, if statin-induced myopathy
has been reported to be slightly increased among patients
with renal failure [15], simvastatin does not seem to increase
muscle disorders in patients with chronic kidney disease,
even requiring peritoneal dialysis [19, 20].
In conclusion, this case illustrates the potentially dan-
gerous interactions of some statins (simvastatin) with drugs
that are also metabolized by the CYP3A4/5 pathway, even
in the absence of genetic predisposing factors. While the
US Food and Drug Administration (FDA) has advised that
the daily dose of simvastatin should not exceed 20mg in
patients taking amlodipine concomitantly, the introduction
of a new drug, even considered as a weak CYP3A4 inhibitor
like ciprofloxacin, could increase the risk of myotoxicity [21].
Consent
Awritten authorization was obtained from the patient for the
publication.
Conflict of Interests
The authors declare that there is no conflict of interests
regarding the publication of this paper.
References
[1] E. Goffin, L. Herbiet, D. Pouthier et al., “Vancomycin and
ciprofloxacin: systemic antibiotic administration for peri-
toneal dialysis-associated peritonitis,” Peritoneal Dialysis Inter-
national, vol. 24, no. 5, pp. 433–439, 2004.
[2] D. P. Kofteridis, A. Valachis, K. Perakis, S. Maraki, E. Daphnis,
andG. Samonis, “Peritoneal dialysis-associated peritonitis: clin-
ical features and predictors of outcome,” International Journal of
Infectious Diseases, vol. 14, no. 6, pp. e489–e493, 2010.
[3] X. Bosch, E. Poch, and J. M. Grau, “Rhabdomyolysis and acute
kidney injury,” The New England Journal of Medicine, vol. 361,
no. 1, pp. 62–72, 2009.
[4] R. Zutt, A. van der Kooi, G. Linthorst, R. Wanders, and M. de
Visser, “Rhabdomyolysis: review of the literature,”Neuromuscu-
lar Disorders, vol. 24, no. 8, pp. 651–659, 2014.
[5] C. Baigent, A. Keech, P. M. Kearney et al., “Efficacy and safety
of cholesterol-lowering treatment: prospective meta-analysis of
data from 90 056 participants in 14 randomised trials of statins,”
The Lancet, vol. 366, no. 9493, pp. 1267–1278, 2005.
[6] P.D.Thompson, P. Clarkson, andR.H.Karas, “Statin-associated
myopathy,”The Journal of theAmericanMedical Association, vol.
289, no. 13, pp. 1681–1690, 2003.
[7] P. Mendes, P. G. Robles, and S. Mathur, “Statin-induced rhab-
domyolysis: a comprehensive review of case reports,” Physio-
therapy Canada, vol. 66, no. 2, pp. 124–132, 2014.
[8] T. Prueksaritanont, B. Ma, and N. Yu, “The human hepatic
metabolism of simvastatin hydroxy acid is mediated primarily
by CYP3A, and not CYP2D6,” British Journal of Clinical Phar-
macology, vol. 56, no. 1, pp. 120–124, 2003.
[9] H. Son, D. Lee, L. A. Lim, S. B. Jang, H. Roh, and K.
Park, “Development of a pharmacokinetic interaction model
for co-administration of simvastatin and amlodipine,” Drug
Metabolism and Pharmacokinetics, vol. 29, no. 2, pp. 120–128,
2014.
[10] Y.-T. Zhou, L.-S. Yu, S. Zeng, Y.-W. Huang, H.-M. Xu, and Q.
Zhou, “Pharmacokinetic drug-drug interactions between 1,4-
dihydropyridine calcium channel blockers and statins: factors
determining interaction strength and relevant clinical risk
management,”Therapeutics and Clinical Risk Management, vol.
10, no. 1, pp. 17–26, 2014.
[11] C. W. Holtzman, B. S. Wiggins, and S. A. Spinler, “Role of P-
glycoprotein in statin drug interactions,” Pharmacotherapy, vol.
26, no. 11, pp. 1601–1607, 2006.
[12] M. S. Park, H. Okochi, and L. Z. Benet, “Is ciprofloxacin a
substrate of p-glycoprotein?” Archives of Drug Information, vol.
4, no. 1, pp. 1–9, 2011.
[13] L. C. J. Ellis, G. M. Hawksworth, and R. J. Weaver, “ATP-
dependent transport of statins by human and rat MRP2/Mrp2,”
Toxicology and Applied Pharmacology, vol. 269, no. 2, pp. 187–
194, 2013.
[14] W. J. Canestaro,M. A. Austin, and K. E.Thummel, “Genetic fac-
tors affecting statin concentrations and subsequent myopathy:
a HuGENet systematic review,”Genetics in Medicine, vol. 16, no.
11, pp. 810–819, 2014.
4 Case Reports in Nephrology
[15] E. Link, S. Parish, J. Armitage et al., “SLCO1B1 variants and
statin-induced myopathy—a genomewide study,”TheNew Eng-
land Journal of Medicine, vol. 359, no. 8, pp. 789–799, 2008.
[16] R. D. Sawant, “Rhabdomyolysis due to an uncommon inter-
action of ciprofloxacin with simvastatin,” Canadian Journal of
Clinical Pharmacology, vol. 16, no. 1, pp. e78–e79, 2009.
[17] N. Fountoulakis, L. Khafizova, M. Logothetis, G. Fanti, and J. A.
Papadakis, “Case report of rhabdomyolysis possibly associated
to the interaction of ciprofloxacin with simvastatin,” Hellenic
Journal of Atherosclerosis, vol. 1, no. 1, pp. 65–67, 2013.
[18] H. Y. Meltzer and P. A. Holy, “Black-white differences in serum
creatine phosphokinase (CPK) activity,” Clinica Chimica Acta,
vol. 54, no. 2, pp. 215–224, 1974.
[19] C. Baigent,M. J. Landray, C. Reith et al., “The effects of lowering
LDL cholesterol with simvastatin plus ezetimibe in patientswith
chronic kidney disease (Study of Heart and Renal Protection):
a randomised placebo-controlled trial,”The Lancet, vol. 377, no.
9784, pp. 2181–2192, 2011.
[20] D. Saltissi, C. Morgan, R. J. Rigby, and J. Westhuyzen, “Safety
and efficacy of simvastatin in hypercholesterolemic patients
undergoing chronic renal dialysis,” The American Journal of
Kidney Diseases, vol. 39, no. 2, pp. 283–290, 2002.
[21] FDA Drug Safety Communication, New Restrictions, Con-
traindications, and Dose Limitations for Zocor (Simvastatin)
to Reduce the Risk of Muscle Injury, US Food and Drug
Administration, 2014, http://www.fda.gov/Drugs/DrugSafety/
ucm256581.htm.
